Abstract：Objective To systematically review the diagnostic value of miRNAs for Alzheimer’s disease.Methods According to the inclusion and exclusion criteria, articles were selected from medical electronic databases, including Pubmed, Web of Science and CNKI. Meta-analysis was performed using Stata 13.0 software.Results A total of ten articles involving twenty studies were included. The Results of meta-analysis showed that the pooled Sen was 0.87[95%CI(0.79,0.91)],pooled Spe was 0.84[95%CI(0.79,0.91)],pooled PLR was 5.23[95%CI(3.04,9.24)],pooled NLR was 0.16[95%CI(0.10,0.26)],pooled DOR was 32.86[95%CI(13.73,78.59)],and the AUC of SROC was 0.92[95%CI(0.89,0.94)]. Conclusions Current evidence suggests that miRNAs may be a specific index to diagnose AD. But because of the limited quality and publication bias of the included studies, more high-quality studies are needed to verify the above conclusion.
单煜恒, 林彦琛, 钟士江. miRNAs对阿尔茨海默病诊断价值的Meta分析[J]. 武警医学, 2019, 30(7): 584-587.
GONG Huaqu, XING Lina, DAI Xuemei, WANG Haiyang. Diagnostic value of MiRNAs for Alzheimer’s disease: a meta-analysis. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(7): 584-587.
Montgomery W, Ueda K, Jorgensen M, et al. Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer’s disease in Japan[J]. Clinicoecon Outcomes Res, 2018, 10(1): 13-28.
[2]
Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: implications for pharmacogenomics and drug response[J]. Int J Mol Sci, 2015, 16(12): 30483-30543.
[3]
Sattlecker M, Kiddle S J, Newhouse S, et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology[J]. Alzheimers Dement, 2014, 10(6): 724-734.
[4]
Chen F C. Alternative RNA structure-coupled gene regulations in tumorigenesis[J]. Int J Mol Sci, 2014, 16(1): 452-475.
[5]
Dang Y, Wei X, Xue L, et al. Long non-coding RNA in glioma: target miRNA and signaling pathways[J]. Clin Lab, 2018, 64(6): 887-894.
[6]
Gupta P, Bhattacharjee S, Sharma A R, et al. miRNAs in Alzheimer disease - a therapeutic perspective[J]. Curr Alzheimer Res, 2017, 14(11): 1198-1206.
[7]
Rupaimoole R, Slack F J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3): 203-222.
[8]
Gauthier S, Leuzy A, Racine E, et al. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues[J]. Prog Neurobiol, 2013, 110: 102-113.
[9]
Kumar P, Dezso Z, MacKenzie C, et al. Circulating miRNA biomarkers for Alzheimer's disease[J]. PLoS One, 2013, 8(7): 1-12.
[10]
Leidinger P, Backes C, Deutscher S, et al. A blood based 12-miRNA signature of Alzheimer disease patients[J]. Genome Biol, 2013, 14(7): R78.
[11]
Tan L, Yu J T, Tan M S, et al. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer’s disease[J]. J Alzheimers Dis, 2014, 40(4): 1017-1027.
[12]
Tan L, Yu J T, Liu Q Y, et al. Circulating miR-125b as a biomarker of Alzheimer's disease[J]. J Neurol Sci, 2014, 336(1-2): 52-56.
[13]
Bhatnagar S, Chertkow H, Schipper H M, et al. Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma[J]. Front Mol Neurosci, 2014, 7: 2.
[14]
Cheng L, Doecke J D, Sharples R A, et al. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment[J]. Mol Psychiatry, 2015, 20(10): 1188-1196.
[15]
Yilmaz S G, Erdal M E, Ozge A A, et al. Can peripheral microRNA expressiondata serve as epigenomic (upstream) biomarkers of Alzheimer’s disease?[J]. OMICS, 2016, 20(8): 456-461.
[16]
Muller M, Jakel L, Bruinsma I B, et al. MicroRNA-29a is a candidate biomarker for Alzheimer's disease in cell-free cerebrospinal fluid[J]. Mol Neurobiol, 2016, 53(5): 2894-2899.
[17]
Ragusa M, Bosco P, Tamburello L, et al. miRNAs plasma profiles in vascular dementia: biomolecular data and biomedical implications[J]. Front Cell Neurosci, 2016, 10: 51.
[18]
Nagaraj S, Laskowska-Kaszub K, Debski K J, et al. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects[J]. Oncotarget, 2017, 8(10): 16122-16143.
[19]
Spence J, Chintapenta M, Kwon H I, et al. A brief review of three common supplements used in Alzheimer's disease[J]. Consult Pharm, 2017, 32(7): 412-414.
2019, Vol. 30 
